Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study of Intrathecal Combination Therapy With the PD-1/VEGF Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

NCT06809517 is registered in ClinicalTrials.gov with Guangzhou Medical University as lead sponsor.

NCT NCT06809517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06809517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study of Intrathecal Combination Therapy With the PD-1/VEGF Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Lead sponsor
Guangzhou Medical University
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 18, 2025
Completion date
May 1, 2026
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intrathecal drug delivery, leptomeningeal metastasis